Patent · US Active

System and method for evaluating impaired glucose tolerance and diabetes mellitus within a patient using an implantable medical device

US7462150B1 · kind B1 · utility

24Cited by
7References
16Claims
0Family size

Assignee

Inventor

Key dates

Filing dateJun 9, 2006
Grant dateDec 9, 2008
Priority date
Expiry dateAug 8, 2027

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61N1/36592
  • WIPO fieldMedical technology
  • WIPO sectorInstruments

Abstract

Techniques are described for use by a pacemaker or implantable cardioverter/defibrillator (ICD) or other implantable medical device. The techniques are provided for evaluating the likelihood that the patient, in which the device is implanted, has impaired glucose tolerance (IGT) or diabetes mellitus. Briefly, a value representative of sleep quality of the patient is detected and then the likelihood that the patient has IGT or diabetes mellitus is determined based on the sleep quality value. In this regard, it has been found that a decrease in overall sleep quality is associated with an increased likelihood of IGT or diabetes mellitus, which is in turn associated with an increased risk of mortality. Hence, sleep quality may be used as a proxy for evaluating the likelihood that the patient has IGT or diabetes mellitus and for assessing associated mortality risk.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.